GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » Gross Margin %

SI-BONE (SI-BONE) Gross Margin % : 73.80% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is SI-BONE Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. SI-BONE's Gross Profit for the three months ended in Dec. 2023 was $28.7 Mil. SI-BONE's Revenue for the three months ended in Dec. 2023 was $38.9 Mil. Therefore, SI-BONE's Gross Margin % for the quarter that ended in Dec. 2023 was 73.80%.

Warning Sign:

SI-BONE Inc gross margin has been in long-term decline. The average rate of decline per year is -2.5%.


The historical rank and industry rank for SI-BONE's Gross Margin % or its related term are showing as below:

SIBN' s Gross Margin % Range Over the Past 10 Years
Min: 78.78   Med: 88.15   Max: 91.27
Current: 78.78


During the past 8 years, the highest Gross Margin % of SI-BONE was 91.27%. The lowest was 78.78%. And the median was 88.15%.

SIBN's Gross Margin % is ranked better than
88.57% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.575 vs SIBN: 78.78

SI-BONE had a gross margin of 73.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for SI-BONE was -2.50% per year.


SI-BONE Gross Margin % Historical Data

The historical data trend for SI-BONE's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE Gross Margin % Chart

SI-BONE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 89.91 87.87 88.43 85.24 78.78

SI-BONE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.07 81.89 81.03 79.30 73.80

Competitive Comparison of SI-BONE's Gross Margin %

For the Medical Devices subindustry, SI-BONE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SI-BONE's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SI-BONE's Gross Margin % distribution charts can be found below:

* The bar in red indicates where SI-BONE's Gross Margin % falls into.



SI-BONE Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

SI-BONE's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=109.4 / 138.886
=(Revenue - Cost of Goods Sold) / Revenue
=(138.886 - 29.466) / 138.886
=78.78 %

SI-BONE's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=28.7 / 38.859
=(Revenue - Cost of Goods Sold) / Revenue
=(38.859 - 10.183) / 38.859
=73.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


SI-BONE  (NAS:SIBN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

SI-BONE had a gross margin of 73.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


SI-BONE Gross Margin % Related Terms

Thank you for viewing the detailed overview of SI-BONE's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


SI-BONE (SI-BONE) Business Description

Traded in Other Exchanges
N/A
Address
471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Executives
Anshul Maheshwari officer: Chief Financial Officer 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Davis Timothy E Jr director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Anthony J Recupero officer: Chief Commercial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn director, officer: Chairman, President & CEO C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis officer: Chief Financial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky officer: GC & Chief Compliance Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh director 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Skyline Venture Partners V Lp 10 percent owner 525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling officer: CMO and VP, Medical Affairs C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby officer: Chief Technology Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451